Phase I Evaluation of ISIS 3521, an Antisense Oligodeoxynucleotide to Protein Kinase C-Alpha, in Patients With Advanced Cancer
Authors:
- 1 November 1999
- journal article
- case report
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 17 (11) , 3586-3595
Abstract
PURPOSE: To determine the maximum-tolerated dose (MTD) and pharmacologic behavior of ISIS 3521 (ISI 641A), an antisense phosphorothioate oligonucleotide to protein kinase C-alpha.PATIENTS AND METHODS: Thirty-six patients with advanced cancer received 99 cycles of ISIS 3521 (0.15 to 6.0 mg/kg/d) as a 2-hour intravenous infusion administered three times per week for 3 consecutive weeks and repeated every 4 weeks. Plasma and urine sampling was performed during the first week of treatment and subjected to capillary gel electrophoresis to determine full-length antisense oligonucleotide in addition to chain-shortened metabolites.RESULTS: Drug-related toxicities included mild to moderate nausea, vomiting, fever, chills, and fatigue. Hematologic toxicity was limited to thrombocytopenia (grade 1, four patients; grade 2, one patient; grade 3, one patient). There was no relationship between dose, maximum concentration of the drug (Cmax), or area under the plasma concentration versus time curve (AUC) and coagulation times or complement levels. Dose escalation was discontinued because of the attainment of peak plasma concentrations, which approached that associated with complement activation in primates. Two patients with non-Hodgkin's lymphoma who completed 17 and nine cycles of therapy achieved complete responses. The pharmacokinetic profile of ISIS 3521 revealed a short elimination half-life (18 to 92 minutes), as well as a dose-dependent decrease in clearance and dose-dependent increases in Cmax, AUC, and elimination half-life.CONCLUSION: No dose-limiting toxicity of ISIS 3521 was identified, and clinical activity was observed. A short elimination half-life was identified, which suggests that alternate schedules with prolonged administration may be necessary for further clinical development.Keywords
This publication has 30 references indexed in Scilit:
- The Protein Kinase C Activator, Phorbol Ester, Elicits Disparate Functional Responses in Androgen-Sensitive and Androgen-Independent Human Prostatic Cancer CellsBiochemical and Biophysical Research Communications, 1998
- Characterization and Modulation of Immune Stimulation by Modified OligonucleotidesAntisense and Nucleic Acid Drug Development, 1997
- Evaluation of the Toxicity of ISIS 2302, a Phosphorothioate Oligonucleotide, in a 4-Week Study in CD-1 MiceAntisense and Nucleic Acid Drug Development, 1997
- BCL-2 antisense therapy in patients with non-Hodgkin lymphomaThe Lancet, 1997
- Comparison of the toxicity profiles of ISIS 1082 and ISIS 2105, phosphorothioate oligonucleotides, following subacute intradermal administration in Sprague-Dawley ratsToxicology, 1997
- Progress in Antisense Oligonucleotide TherapeuticsAnnual Review of Pharmacology and Toxicology, 1996
- CpG motifs in bacterial DNA trigger direct B-cell activationNature, 1995
- Involvement of the α Isoenzyme of Protein Kinase C in the Growth Inhibition Induced by Phorbol Esters in MH1C1 Hepatoma CellsBiochemical and Biophysical Research Communications, 1994
- Therapeutic Applications of OligonucleotidesAnnual Review of Pharmacology and Toxicology, 1992
- The molecular heterogeneity of protein kinase C and its implications for cellular regulationNature, 1988